BRPI0400341A - Process for obtaining purified bhk-21 cell rabies vaccine for veterinary use and its resulting vaccine - Google Patents

Process for obtaining purified bhk-21 cell rabies vaccine for veterinary use and its resulting vaccine

Info

Publication number
BRPI0400341A
BRPI0400341A BRPI0400341A BRPI0400341A BR PI0400341 A BRPI0400341 A BR PI0400341A BR PI0400341 A BRPI0400341 A BR PI0400341A BR PI0400341 A BRPI0400341 A BR PI0400341A
Authority
BR
Brazil
Prior art keywords
vaccine
bhk
veterinary use
resulting
obtaining purified
Prior art date
Application number
Other languages
Portuguese (pt)
Inventor
Neuza Maria Frazatti Gallina
Original Assignee
Fundacao Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Butantan filed Critical Fundacao Butantan
Priority to BRPI0400341 priority Critical patent/BRPI0400341B1/en
Publication of BRPI0400341A publication Critical patent/BRPI0400341A/en
Publication of BRPI0400341B1 publication Critical patent/BRPI0400341B1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"PROCESSO DE OBTENçãO DE VACINA ANTI-RáBICA EM CéLULAS BHK-21, PURIFICADA, PARA USO VETERINáRIO, E RESPECTIVA VACINA RESULTANTE". Processo este que prevê a obtenção da vacina através da produção do vírus em biorreator, da purificação por cromatografia e do uso da albumina eq³ina como estabilizador e otimizador da resposta imune humoral; a vacina anti-rábica resultante do referido processo é uma suspensão de vírus rábico da cepa PV (Pasteur Virus), obtida de células BHK-21 infectadas, purificada e inativada pela Betapropiolactona, vacina esta que é apresentada na forma liofilizada e utiliza a albumina eq³ina como estabilizador."PROCESS FOR OBTAINING AN ANTI-RABIC VACCINE IN BHK-21 CELLS, PURIFIED, FOR VETERINARY USE, AND RESPECTIVE VACCINE VACCINE". This process provides for obtaining the vaccine through production of the virus in bioreactor, purification by chromatography and the use of equine albumin as a stabilizer and optimizer of humoral immune response; the rabies vaccine resulting from said process is a suspension of the PV strain (Pasteur Virus) rabies virus, obtained from infected BHK-21 cells, purified and inactivated by Betapropiolactone, which vaccine is presented in lyophilized form and uses the equine as a stabilizer.

BRPI0400341 2004-02-02 2004-02-02 PROCESS FOR OBTAINING PURIFIED BHK-21 CELL ANTI-RABIC VACCINE FOR VETERINARY USE AND RESPECTIVE VACCINE BRPI0400341B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0400341 BRPI0400341B1 (en) 2004-02-02 2004-02-02 PROCESS FOR OBTAINING PURIFIED BHK-21 CELL ANTI-RABIC VACCINE FOR VETERINARY USE AND RESPECTIVE VACCINE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0400341 BRPI0400341B1 (en) 2004-02-02 2004-02-02 PROCESS FOR OBTAINING PURIFIED BHK-21 CELL ANTI-RABIC VACCINE FOR VETERINARY USE AND RESPECTIVE VACCINE

Publications (2)

Publication Number Publication Date
BRPI0400341A true BRPI0400341A (en) 2005-10-11
BRPI0400341B1 BRPI0400341B1 (en) 2014-01-07

Family

ID=35062855

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0400341 BRPI0400341B1 (en) 2004-02-02 2004-02-02 PROCESS FOR OBTAINING PURIFIED BHK-21 CELL ANTI-RABIC VACCINE FOR VETERINARY USE AND RESPECTIVE VACCINE

Country Status (1)

Country Link
BR (1) BRPI0400341B1 (en)

Also Published As

Publication number Publication date
BRPI0400341B1 (en) 2014-01-07

Similar Documents

Publication Publication Date Title
ES2459166T3 (en) Procedure for the production of viral vaccines
AR039465A1 (en) MULTI PLASMID SYSTEM FOR THE PRODUCTION OF VIRUS INFLUENZA
AR059772A1 (en) COMPOSITIONS THAT INCLUDE HEMAGLUTININE ELABORATION METHODS AND METHODS OF THE SAME USE
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
FR08C0046I2 (en) IN VITRO RECONSTRUCTION OF SEGMENTED POLARITY-NEGATIVE RNA VIRUSES
EA201000195A1 (en) VIRUS-LIKE PARTICLES OF INFLUENZA VIRUS, INCLUDING HEMAGGLUTININ, PRODUCED IN PLANTS
ATE469972T1 (en) MULTIPLASMID SYSTEM FOR GENERATING THE FLU VIRUS
NZ577405A (en) Vaccines including antigen from four strains of influenza virus
ES2139553T1 (en) REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION.
DK1358319T3 (en) Live influenza vaccine and its method of preparation
BRPI0516221A (en) method of virus production from a cell culture, composition, and method of production of infectious reovirus
BRPI0612268A2 (en) Isolated nucleic acid, expression vector, Methods for producing a genomic influenza rna, for producing a recombinant influenza virus, for generating a recombinant negative strand segmented rna virus in cultured canine cells, and for generating infectious influenza viral particles in cells cultivated canines, cell and virus
EA200801756A1 (en) ANTIGRIPOPOSIC VACCINES CONTAINING HEMAGGLUTININ AND PROTEINS OF MATRIX
AR039783A1 (en) IMPROVED METHODS OF VIRAL PURIFICATION
NO20054608L (en) Influenza vaccine
AR056133A1 (en) CANINE INFLUENZA VIRUSES AND RELATED COMPOSITIONS AND METHODS OF USE
BRPI0809842B8 (en) process for obtaining continuous diploid avian cell lines, process of replicating a virus in a continuous diploid avian cell line, and process for producing recombinant peptides and proteins
BRPI0410340A (en) vectors and cells for preparing transgenic plant-derived immunoprotective compositions
CY1113225T1 (en) REDUCTION OF POSSIBLE MEDICAL RISKS CONNECTED WITH INFLUENZA VACCINE
EA201001198A1 (en) RECOMBINANT VIRUS-LIKE PARTICLES (HF), RELATED TO THE INFLUENZA VIRUS, PRODUCED IN TRANSGENIC PLANTS, EXPRESSING HEMAGGLUTININ
ATE482714T1 (en) MODIFIED HEAT SHOCK PROTEIN-ANTIGEN PEPTIDE COMPLEX
DK1159405T3 (en) Viral particles released after human cytomegalovirus infection and their use as a vaccine
EP2351843A3 (en) Rabies virus vector systems and compositions and methods thereof
WO2005115448A8 (en) Multi plasmid system for the production of influenza virus
DK1796717T3 (en) combination vaccine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B09A Decision: granting
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2004, OBSERVADAS AS CONDICOES LEGAIS.